Peptide duration and measured outcomes
The longest signal and the most useful result are separate questions.
Exposure beside outcome
My quarrel with a peptide ranking begins when it awards points for duration before deciding what the exposure is meant to accomplish. Here are the observations I would put alongside each other. They come from separate studies, with different populations, routes and measurements; this is a comparison of research questions rather than a head-to-head trial.
| Compound | Exposure or hormone response | Outcome actually studied |
|---|---|---|
| Sermorelin | Rapid peptide clearance, with GH elevated for about three hours in healthy men | Height velocity in children with GH deficiency; short-term hormone responses in older men |
| Tesamorelin | Stimulates endogenous GH through the GHRH receptor | Visceral-fat reduction in adults with HIV, sustained during continued treatment and reversed after discontinuation |
| CJC-1295 DAC | Multi-day GH and IGF-1 elevation in healthy adults | Early pharmacology and pulsatility measurements; clinical benefit unestablished |
| Ipamorelin | Approximately two-hour terminal half-life and an acute GH pulse in volunteers | Postoperative meal tolerance in adults; primary endpoint missed |
Receptor and persistence
Sermorelin, tesamorelin and CJC-1295 activate the GHRH receptor. Ipamorelin activates the ghrelin receptor. The GHRH review describes how analogue design and receptor biology affect the response. A shared downstream hormone gives these compounds a relationship, while the route and persistence of stimulation distinguish them.
The albumin-binding DAC form of CJC-1295 is the clearest duration experiment here. The no-DAC peptide lacks that binding element, so its name cannot be used as shorthand for the multi-day trial findings. Informal comparisons that merge them lose the feature being compared.
After the intervention
Tesamorelin offers the most direct observation of what happened to a clinical fat outcome after discontinuation. I value that follow-up because a result can be useful and reversible at the same time. Its return toward baseline neither erases the treatment effect nor demonstrates a permanent change.
The other records leave different gaps. Short-term sermorelin endocrine responses cannot establish enduring adult wellness benefits. CJC-1295’s sustained blood measurements leave clinical outcomes open. Ipamorelin’s ferret weight result and rat bone-growth result remain animal findings, alongside a missed human postoperative endpoint.
None of those gaps is filled by combining peptide names. The cited human records here do not establish outcomes for CJC-1295 paired with ipamorelin. The FAQ addresses that combination claim and the other recurring terminology questions.